Evaluation of treatment of local bladder cancer with Bacille Calmette-Guérin (BCG). Is treatment follow up in the outpatient department just as good as follow up in the operating theatre?

Detection rate of carcinoma in situ (CIS) after intravesical Bacille Calmette-Guérin (BCG) in fluorescence guided flexible cystoscopy in the outpatient department (OPD) compared to fluorescence guided cystoscopy in rigid cystoscopes in the operating theatre (OT).

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN48222814

Enrollment

Registered

2012-01-20

Start date

2011-12-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer of the urinary bladder - carcinoma of the bladder - CIS Cancer Malignant neoplasm of bladder

Interventions

Fluorescence guided cystoscopy and biopsy in rigid scopes in the operating theatre and in flexible cystoscopes in the outpatient department

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who have had 6 weekly BCG bladder instillations as treatment of primary or secondary carcinoma in situ of the bladder.

Exclusion criteria

Exclusion criteria: Patients who do not understand Danish or who the investigators do not find able to fulfil the study

Design outcomes

Primary

Measure	Time frame
Histological diagnosis from evaluation of bladder biopsy	—

Secondary

Measure	Time frame
Quality of life and pain in relation to test procedures	—

Countries

Denmark

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026